优化成人恶性血液病双份脐血移植的移植物选择
该回顾性分析纳入1375例接受双份无关脐血移植的成人恶性血液病患者,评估移植物选择标准对结局的影响。结果显示,冻存总核细胞剂量≤3.5×10^7/kg、HLA错配≥2个及ABO不相合是总生存的独立危险因素;优势脐血CD34+细胞≥0.7×10^5/kg与更好的总生存相关。数据支持选择HLA匹配良好、每份脐血冻存TNC>3.5×10^7/kg且CD34+≥0.7×10^5/kg的移植物。
要点
- 双份脐血移植应选择HLA错配0-1个的脐血单位。
- 每份脐血冻存TNC应>3.5×10^7/kg,CD34+应≥0.7×10^5/kg。
- 避免ABO主侧/次侧不相合可改善总生存。
核心结论
- 双份脐血移植选择HLA匹配良好、每份冻存TNC>3.5×10^7/kg且CD34+≥0.7×10^5/kg的脐血单位可改善结局。
研究设计与样本
- 回顾性分析1375例接受双份无关脐血移植的成人恶性血液病患者,评估移植物选择标准与移植结局的关系。
关键数值与推荐
- 推荐选择HLA错配0-1个的脐血单位。
- 推荐每份脐血冻存TNC>3.5×10^7/kg。
- 推荐优势脐血CD34+细胞剂量≥0.7×10^5/kg。
临床怎么用
- 成人双份脐血移植选移植物时,应优先考虑HLA匹配度、TNC剂量和CD34+剂量。
- 尽量避免选择ABO主侧或次侧不相合的脐血单位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Double-unit unrelated cord blood transplantation (DUCBT) is an option in patients for whom a single unit is not sufficient to provide an adequate number of cells. As current guidelines on UCB unit selection are mainly based on single-unit UCB data, we performed a retrospective analysis of 1375 adult recipients of DUCBT for hematologic malignancies to determine optimal criteria for graft selection. Cryopreserved total nucleated cells (TNCs; ≤3.5 vs >3.5 × 107/kg: hazard ratio [HR], 1.53; 30% vs 45%; P = .01), number of HLA mismatches (≥2 vs 0-1: HR, 1.28; 42% vs 48%; P = .01), and ABO compatibility (minor/major ABO incompatibility vs compatibility: HR, 1.28; P = .04) were independent risk factors for OS. Cryopreserved CD34+ cell dose ≥0.7 × 105/kg in the winning UCB was associated with improved OS (HR, 1.34; P = .03). Low TNC (≤3.5 × 107/kg) and CD34+ (≤1.4 × 105/kg) cell doses were related to decreased neutrophil recovery (HR, 0.65 [P = .01] and HR, 0.81 [P = .01], respectively). DUCBT recipients with ≥2 HLA mismatches had a higher incidence of grade II-IV and III-IV acute graft-versus-host disease (HR, 1.26 [P = .03] and 1.59 [P = .02], respectively). Low TNC dose (HR, 1.57; P = .02) and receiving UCB with ≥2 HLA mismatches (HR, 1.35; P = .03) were associated with increased transplant-related mortality. Our data support selecting adequately HLA-matched UCB units with a double-unit cryopreserved TNC dose >3.5 × 107/kg and CD34+ cell dose of ≥0.7 × 105/kg per unit in DUCBT candidates.
引用
- Fatobene G, Volt F, Moreira F, et al. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Adv. 2020. PMID: 33351128. doi:10.1182/bloodadvances.2020002258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。